Junior Group Leader positions - call for ECRs to establish their first independent lab
Call for Early Career Cancer Researchers with or applying for external fellowship funding to establish their first independent laboratory at the Cancer Research UK Scotland Institute and School of Cancer Sciences, University of Glasgow.
Find out more and register your interest here.
College Futures Fellowship Scheme announced
17th June 2024
As part of its 2033 vision, the University of Glasgow's College of Medical Veterinary and Life Sciences (MVLS) today launched the start of its ambitious recruitment programme, the College Futures Fellowship Scheme. MVLS is looking to recruit up to 10 fellows, who will be hosted within its Schools, including the School of Cancer Sciences, and woven into the fabric of its 4 College Futures.
These prestigious 5-year opportunities for early career academics represent the College's commitment to nurture talent and foster the next generation of leaders. You can find more details within its newly developed Recruitment Hub, which also houses content showcasing the College’s Shared Research Facilities and continued commitment to Equality, Diversity and Inclusion (EDI), plus training and development opportunities.
CRUK Scotland Institute and Oxford Drug Design awarded MRC grant funding to advance novel cancer therapeutics discovery
The Cancer Research UK Scotland Institute and Oxford Drug Design, a biotechnology company with core expertise in AI drug discovery, have announced that their joint application for the MRC (UK Medical Research Council) National Mouse Genetics Network (NMGN) Business Engagement Fund has been awarded.
CRUK Scotland Institute partners with DEBRA UK to tackle early onset cancer in patients with RDEB
The CRUK Scotland Institute has launched a new long-term research partnership with DEBRA UK, a national charity and patient support organisation for people living with or directly affected by the rare genetic skin condition epidermolysis bullosa (EB).
This 5-year partnership will focus on the devlopment of pre-clinical cancer models that will help increase understanding around the progression of skin cancer in patients living with recessive dystrophic epidermolysis bullosa (RDEB).
Dr Fieke Froeling and Team SAMBAI receive £20m Cancer Grand Challenges award
A global, interdisciplinary team of researchers, including Dr Fieke Froeling has been selected to receive a Cancer Grand Challenges award of up to £20m over five years to tackle the Cancer inequities challenge
Prof Owen Sansom elected to EMBO Membership
9 July 2024
In EMBO's 60th anniversary year, 120 scientists from across Europe and beyond have been elected to the EMBO Membership, an honour that celebrates research excellence and outstanding achievements in the life sciences. Prof Owen Sansom, Director of the CRUK Scotland Institute, is one of these newly elected members. Read more about EMBO and the other newly elected members here.
Owen runs the Colorectal Cancer and Wnt Signalling lab at the Institute, the team is interrogating the molecular mechanisms underpinning colorectal cancer initiation and progression, with the overarching goals to identify early-stage diagnostic biomarkers and stage- and subtype-specific targeted therapies.
Dr Zoi Diamantopoulou awarded prestigious Future Leaders Fellowship
18 July 2024
Dr Zoi Diamantopoulou has been awarded a UKRI Future Leaders Fellowship (FLF), a scheme which provides long-term support to enable fellows to tackle new or emerging research. Zoi will use her FLF programme to investigate how the circadian rhythm controls the spread of cancer – metastasis.
Publication Highlights: September & October 2023
Piotr Dzien, Karen Blyth, David Lewis, and colleagues have published an article in Cancer & Metabolism that proposes positron emission tomography (PET) imaging of the sodium iodide symporter (NIS) as a rapid and sensitive in vivo test for metabolic treatments targeting energetic pathways. This new approach makes in vivo testing more practical, giving an immediate readout after a single dose; it reduces drug costs, animal use, and the time associated with long therapeutic studies.
Publication Highlights: November & December 2023
New research from across the Sansom, Bushell, Le Quesne, Norman and Coffelt labs at the CRUK Scotland Institute released on BioRxiv has shown that eIF4A1 is specifically required to support the translational demands of oncogenic Wnt signalling. The team report the suppression of intestinal tumourigenesis in colorectal cancer models following loss of eIF4A1 and argue that deregulated/increased translational reprogramming should be considered a prerequisite/hallmark of cancer and not simply a marker of increased proliferation.
Research with integrity - making a statement
New CRUK blog post written by Catherine Winchester desribes the value of creating annual statements on research integrity. Catherine, Senior Research Advisor - Grants and Research Integrity at the CRUK Scotland Institute, explains what an annual statement on research intergrity is, what it can tell us and looks to the future of annual research integrity statements.
Read Catherine's blog here.
Cancer Research UK announces its largest ever investment in Scotland
Cancer Research UK have announced their biggest ever investment in Scotland which will be awarded to the Beatson Institute, now being renamed as the Cancer Research UK Scotland Institute. The funding will be up to £123 million over a seven-year period and will support around 300 researchers and 100 support staff across 30 research groups.
This investment will boost Scotland as a global hub for cancer research on an increasingly competitive worldwide stage and help the recruitment of international talent.
Professor Owen Sansom, the Director of the Institute, has said “This recognition of the hard work and determination of our researchers to find new ways to tackle cancer, as well as improve current treatments, is major boost for both future cancer patients in Scotland and for the newly titled Cancer Research UK Scotland Institute. It represents an unprecedented vote of confidence in Scotland’s scientific prowess.”
Read more here.
Owen Sansom and PLASTICITY-Tx shortlisted for Cancer Grand Challenges funding
Owen Sansom, Director of the Cancer Reserach UK Beatson Institute, has been selected for the final stages of Cancer Grand Challenges as part of team PLASTICITY-Tx. The team will now compete to win up to $25m funding to take on one of cancer's toughest challenges.
Publication Highlights: July & August 2023
Using a novel strain of influenza A and a modified melanoma model system, work by Chiara Pirillo, Ed Roberts and colleagues, published in ScienceImmunology, has shown that co-encoded contextual information and antigen allow resident conventional dendritic cells (rDCs) to be appropriately activated in the lymph node. By determining how immune responses may be improved by elevated rDC function, these findings have important implications on the design of cancer vaccines and immunotherapies.
Dr Johan Vande Voorde interview with Cancer Grand Challenges
Dr Johan Vande Voorde, associate scientist at the Cancer Research UK Beatson Institute, is currently working as part of the Cancer Grand Challenges Rosetta team which focuses on 3D tumour mapping at the molecular and cellular level. This month, he was interviewed by Cancer Grand Challenges about his recent work published in Nature Metabolism.
Read the interview here.
Publication Highlights: May & June 2023
In their recent article in Neuro-Oncology Advances, Dominik Koessinger, David Novo and colleagues identify an inter-cellular communication tool where p53-mutant glioblastoma cells release podocalyxin-containing extracellular vesicles. This stimulates neighbouring brain cells to secrete factors creating an environment favourable to cell invasion and ultimately promoting cancer cell infiltration in the brain. Investigating the tumour microenvironment in this study has potentially highlighted a druggable target for a cancer type with particularly poor prognosis.
Publication Highlights: March & April 2023
Work – published in Molecular Oncology - by recent PhD graduate Declan Whyte from the Murphy lab described a novel role for NUAK1 in chromosome segregation and centrosome duplication during cell division. Although growing evidence has suggested NUAK1 as a potential vulnerability in cancer, in particular in conjunction with KRAS and MYC, the work raises concerns about the application of anti-NUAK1 therapies.
NIH Funding Award
As of January, Dr Payam Gammage's lab begun their NIH MERIT R37 Award with the National Cancer Institute in the US. This award, held jointly with the lab of Dr Ed Reznik at the Memorial Sloan Kettering Cancer Center, will allow the team to define the function of complex I truncating mutations in cancer. Complex I mutations are particularly abundant in colorectal, thyroid and kidney cancers and, alongside a range of other mitochondrial DNA mutations that are present in ~60% of all cancers in total, remain poorly understood. The award is worth ~$4.5M over 7 years (2023-2029) and the team will be split evenly between Glasgow and New York.
Publication Highlights: January & Februrary 2023
Using a lineage tracing model, Stephanie May and colleagues established that pericentral hepatocytes played only a limited role in the regeneration of the liver. Their Axin2CreERT2 knock-in model reconciled previously conflicting reports on the involvement of this cell type and revealed methodological challenges of preclinical modelling. [Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration]
Former PhD student, Vasileios Papalazarou featured in Journal of Cell Science
First Person is a series of interviews with the first authors of a selection of papers published in Journal of Cell Science, helping researchers promote themselves alongside their papers. Vasileios Papalazarou is joint first author on ' Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche', published in JCS.
Publication Highlights: November & December 2022
In their study in Nature Communications, Dustin Flanagan, Owen Sansom and colleagues showed that high TGFβ expression – whose role has been described as contradictory in colorectal cancer – accelerated tumour formation in the context of KRAS and APC mutation. While linked to aggressive disease progression, mechanistically epithelial TGFβ activation stimulated growth factor signalling pathways which as a result is a promising finding for potential drug targeting strategies.
